23andMe Holding EBIT

The latest EBIT for ME is $-170M as of June 2025. That compares with $-85M in the prior-year period — down 93.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside 23andMe Holding's historical trend and sector peers before judging valuation or financial health.

Over the past year, ME's EBIT moved from $-85M to $-170M — a 93.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 23andMe Holding's operating scale or balance-sheet position.

Against Healthcare companies, ME currently prints $-170M for EBIT, while the sector average sits near $110B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at 23andMe Holding's growth, margins, and balance sheet.

A EBIT figure of $-170M for ME is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ME's EBIT ($-170M), review year-over-year change from $-85M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.